Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2024-11-21 Capital/Financing Update
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 98% confidence The document explicitly states it is a "PROSPECTUS SUPPLEMENT (To prospectus dated January 5, 2024)" and is "Filed Pursuant to Rule 424(b)(5) Registration No. 333-276323". This structure, involving the offering of securities (ADSs, Pre-Funded Warrants, Warrants) and referencing SEC filings and registration numbers, is characteristic of a securities offering document filed with the SEC. While the definitions provided do not have a specific code for a Prospectus Supplement, this type of filing is fundamentally related to capital raising and financing activities. Among the provided codes, "Capital/Financing Update (Code: CAP)" is the most appropriate fit, as a prospectus supplement is the primary document detailing a specific securities offering used for capital raising. It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it is highly specific to a financing event.
2024-11-21 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document explicitly states it is an 'Immediate Report' under Israeli regulations for a 'Foreign Corporation' and mentions an attached document titled '*PROSPECTUS SUPPLEMENT*'. A Prospectus Supplement is a document filed with securities regulators (like the ISA and TASE mentioned here) to provide material updates or details regarding an offering of securities, often following an initial registration statement or base prospectus. This type of filing relates directly to capital raising or financing activities. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate classification for a Prospectus Supplement, as it details the terms of a security offering. The document is short and announces the attachment of the supplement, but the core subject matter is financing, making CAP more specific than the general 'RPA' or 'RNS' fallback.
2024-11-21 English
The company intends to publish an immediate report about a material event, trading in its shares will resume after the publication of the report
Report Publication Announcement Classification · 95% confidence The document is a short notice from the Tel-Aviv Stock Exchange regarding a company (BIOLINE RX LTD) intending to publish an immediate report about a material event. It states that trading will be halted until the report is published. The document itself does not contain any financial data or detailed report content but is an announcement about the upcoming report publication. Given the short length (498 characters) and the nature of the content, this fits the criteria for a Report Publication Announcement (RPA) rather than the report itself or any other filing type.
2024-11-21 Hebrew (modern)
Received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 12, 2025, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
Regulatory Filings Classification · 95% confidence The document is explicitly titled "FORM 6-K" and is a "REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934." Form 6-K filings are used by foreign private issuers to report material information that is required to be publicly disclosed in their home country or stock exchange, or that is distributed to their shareholders. This type of filing does not map directly to the specific US-centric codes like 10-K (Annual Report) or ER (Earnings Release). Since it is a mandatory regulatory disclosure that doesn't fit the other specific categories (like AGM, DIRS, DIV, etc.), the most appropriate classification is the general regulatory fallback category, RNS (Regulatory Filings). The document length is short (1954 chars), but it is the report itself, not an announcement *about* a report, so RPA is not appropriate.
2024-11-13 English
Received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 12, 2025, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed under Israeli regulations ('Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000') and references the Tel Aviv Stock Exchange and NASDAQ. The core content is a brief notification stating that the company received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. Crucially, the text explicitly states: 'Attached hereto is a report on *FORM_6-K_13-Nov-2024_isa.pdf*'. Since the document itself is very short (2068 chars) and serves primarily to announce the publication of an attached report (a Form 6-K, which is a general SEC filing for foreign private issuers), it fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is not the full 6-K report itself, but the announcement of it.
2024-11-13 English
6-K
Regulatory Filings
2024-11-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.